Ipsc

Ryne Biotechnology receives grant to advance Parkinson’s therapy

14-Feb-2023 By Rachel Arthur

Ryne Biotechnology has received a $4m Clinical Stage Research Program (CLIN1) grant from the California Institute for Regenerative Medicine (CIRM).

Cellistic acquires Celyad Oncology’s GMP cell therapy manufacturing facility

20-Sep-2022 By Rachel Arthur

Ncardia’s cell therapy development and manufacturing business Cellistic will acquire Celyad Oncology’s GMP grade cell therapy manufacturing capability, covering Celyad’s Mont-Saint-Guibert facility in Belgium and all related staff.

Applied StemCell expands manufacturing facility to support cell and gene therapies

30-Aug-2022 By Rachel Arthur

Applied StemCell is expanding its cGMP facility to increase its cell banking and cell product manufacturing capacity.

Ncardia secures $60m to expand iPSC platform

25-Nov-2021 By Jane Byrne

Ncardia, a human-induced pluripotent stem cell-based (iPSC) technology company, has secured more than US$60m in capital through a strategic partnership with Kiniciti, a US based investor with a focus on the global cell and gene therapy ecosystem.

Team finds way to enhance stem cell therapy for CNS injuries

26-Oct-2021 By Jane Byrne

Researchers say a new technique they have developed paves the way for stem cell therapies to treat central nervous system (CNS) injuries and disease.

Dispatches from Bio Digital 2021

Mogrify looks to transform cell therapy development

01-Jul-2021 By Jane Byrne

Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.

Acquisition of German player gives Catalent enhanced iPSC-based cell therapy capabilities

25-Jun-2021 By Jane Byrne

Catalent is to acquire German company, RheinCell Therapeutics, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies.

UK deal sees consolidation of two players in the iPSC space

18-Mar-2021 By Jane Byrne

Axol Biosciences, a UK provider of human induced pluripotent stem cells (iPSC) derived cells, media, and characterization services, has merged with Scotland based, Censo Biotechnologies, a cell biology CRO with expertise in iPSC-related technologies.